Pfizer is currently offering a substantial 6.6% dividend yield despite facing challenges from upcoming patent expirations on key drugs, which has led to a cautious outlook from Wall Street. However, the company's ability to support its dividend through cash flow rather than earnings may present a valuable opportunity for long-term dividend investors willing to accept some risk.
Pfizer is currently offering a substantial 6.6% dividend yield, significantly higher than the S&P 500 average yield of 1.1%, presenting a potential opportunity for long-term dividend investors willing to accept higher risk. Despite the challenges of upcoming patent expirations and a high payout ratio, Pfizer's ability to sustain its dividend through cash flow suggests a potential for both income and capital appreciation if the market fears surrounding these issues are overestimated.